Amphotericin B as antiviral drug: Possible efficacy against COVID-19

Since its discovery, amphotericin B (AmB) is still one of the most common first-line choices in treatment pulmonary mycoses for over seventh decades from discovery. AmB which is belonged to the polyene group has a wide spectrum in vitro and in vivo antimicrobial activity against fungi and parasites,...

Full description

Bibliographic Details
Main Author: Falah Hasan Obayes AL-Khikani
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Annals of Thoracic Medicine
Subjects:
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=118;epage=124;aulast=AL-Khikani
id doaj-86216d2f10bc4cbcac6c393cbd1f7179
record_format Article
spelling doaj-86216d2f10bc4cbcac6c393cbd1f71792020-11-25T02:51:21ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572020-01-0115311812410.4103/atm.ATM_147_20Amphotericin B as antiviral drug: Possible efficacy against COVID-19Falah Hasan Obayes AL-KhikaniSince its discovery, amphotericin B (AmB) is still one of the most common first-line choices in treatment pulmonary mycoses for over seventh decades from discovery. AmB which is belonged to the polyene group has a wide spectrum in vitro and in vivo antimicrobial activity against fungi and parasites, resistance to AmB is rare despite extensive use. Recently, some studies focused on the potential antimicrobial action of AmB against some enveloped viruses such as human immunodeficiency virus, Japanese encephalitis virus, and rubella virus. Coronaviruses are enveloped positive-sense RNA nucleic acid viruses that have club-like spikes, characterized by a distinctive replication strategy; they are round and sometimes pleomorphic shapes. COVID-19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID-19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there are no specific antiviral drugs or vaccines for 2019-novel coronavirus. Hence, this review may serve as an impetus for researchers working in the field of medical microbiology, vaccination, and antiviral drug design by discussion the most recent information about the antiviral action of AmB against COVID-19 infection as well as trying to a deep understanding of major properties, mechanisms of action, immune system responses, and antimicrobial efficiency of AmB. Since AmB is expected to alter the structure of the viral envelope, membrane integrity of cells, and internal cellular organelles, besides its other unique properties such as host immunomodulatory effects, so this review suggested that AmB as an effective anti-fungi drug thus may hold the promise of formulating a novel therapeutic option to treat COVID-19.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=118;epage=124;aulast=AL-Khikaniamphotericin bantimicrobial agentsantiviral drugscoronaviruscovid-19
collection DOAJ
language English
format Article
sources DOAJ
author Falah Hasan Obayes AL-Khikani
spellingShingle Falah Hasan Obayes AL-Khikani
Amphotericin B as antiviral drug: Possible efficacy against COVID-19
Annals of Thoracic Medicine
amphotericin b
antimicrobial agents
antiviral drugs
coronavirus
covid-19
author_facet Falah Hasan Obayes AL-Khikani
author_sort Falah Hasan Obayes AL-Khikani
title Amphotericin B as antiviral drug: Possible efficacy against COVID-19
title_short Amphotericin B as antiviral drug: Possible efficacy against COVID-19
title_full Amphotericin B as antiviral drug: Possible efficacy against COVID-19
title_fullStr Amphotericin B as antiviral drug: Possible efficacy against COVID-19
title_full_unstemmed Amphotericin B as antiviral drug: Possible efficacy against COVID-19
title_sort amphotericin b as antiviral drug: possible efficacy against covid-19
publisher Wolters Kluwer Medknow Publications
series Annals of Thoracic Medicine
issn 1817-1737
1998-3557
publishDate 2020-01-01
description Since its discovery, amphotericin B (AmB) is still one of the most common first-line choices in treatment pulmonary mycoses for over seventh decades from discovery. AmB which is belonged to the polyene group has a wide spectrum in vitro and in vivo antimicrobial activity against fungi and parasites, resistance to AmB is rare despite extensive use. Recently, some studies focused on the potential antimicrobial action of AmB against some enveloped viruses such as human immunodeficiency virus, Japanese encephalitis virus, and rubella virus. Coronaviruses are enveloped positive-sense RNA nucleic acid viruses that have club-like spikes, characterized by a distinctive replication strategy; they are round and sometimes pleomorphic shapes. COVID-19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID-19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there are no specific antiviral drugs or vaccines for 2019-novel coronavirus. Hence, this review may serve as an impetus for researchers working in the field of medical microbiology, vaccination, and antiviral drug design by discussion the most recent information about the antiviral action of AmB against COVID-19 infection as well as trying to a deep understanding of major properties, mechanisms of action, immune system responses, and antimicrobial efficiency of AmB. Since AmB is expected to alter the structure of the viral envelope, membrane integrity of cells, and internal cellular organelles, besides its other unique properties such as host immunomodulatory effects, so this review suggested that AmB as an effective anti-fungi drug thus may hold the promise of formulating a novel therapeutic option to treat COVID-19.
topic amphotericin b
antimicrobial agents
antiviral drugs
coronavirus
covid-19
url http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=118;epage=124;aulast=AL-Khikani
work_keys_str_mv AT falahhasanobayesalkhikani amphotericinbasantiviraldrugpossibleefficacyagainstcovid19
_version_ 1724735039910969344